Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Lisa M. Rimsza, MD, Michael L. LeBlanc, PhD, Robin A. Roberts, BS, Joseph M. Unger, MS, Thomas P. Miller, MD, Constantine M. Sabalos, MS, Ralph R. Martel, PhD, Elias Campo, MD, Andreas Rosenwald, MD, Joseph M. Connors, MD, Laurie H. Sehn, MD, Natalie Johnson, MD, Randy D. Gascoyne, MD

Blood (2007) 110 (11): 50.

https://doi.org/10.1182/blood.V110.11.50.50

Published: 2007

Journal Articles

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Robin A. Roberts, BS, Lisa M. Rimsza, M.D., Louis Staudt, M.D.Ph.D., Andreas Rosenwald, M.D., Wing-Chung Chan, M.D., Sandeep Dave, M.D., Randy D. Gascoyne, M.D., Joseph M. Connors, M.D., Erlend B. Smeland, M.D.Ph.D., H.K. Muller-Hermelink, M.D., Elias Campo, M.D., Elaine S. Jaffe, M.D., Wyndham Wilson, M.D., Bruce K. Tan, M.D., Richard I. Fisher, M.D., Thomas M. Grogan, M.D., Thomas P. Miller, MD

Blood (2006) 108 (11): 809.

https://doi.org/10.1182/blood.V108.11.809.809

Published: 2006

Journal Articles

Loss of Major Histocompatibility Class II (MHCII) Gene Expression in Diffuse Large B Cell Lymphoma (DLBCL) Is Not Generally Due to Genetic Mutations in the Coding Regions of CIITA or RFX.

Robin A. Roberts, BS, Thomas P. Miller, M.D., Lisa M. Rimsza, MD

Blood (2006) 108 (11): 2039.

https://doi.org/10.1182/blood.V108.11.2039.2039

Published: 2006

Journal Articles

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

Robin A. Roberts, George Wright, Andreas R. Rosenwald, Marina A. Jaramillo, Thomas M. Grogan, Thomas P. Miller, Yvette Frutiger, Wing C. Chan, Randy D. Gascoyne, German Ott, H. Konrad Muller-Hermelink, Louis M. Staudt, Lisa M. Rimsza

Blood (2006) 108 (1): 311–318.

https://doi.org/10.1182/blood-2005-11-4742

Published: 2006

Journal Articles

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

Blood (2006) 107 (3): 1101–1107.

https://doi.org/10.1182/blood-2005-04-1510

Published: 2006

Journal Articles

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Margaret E. Tome, David B. F. Johnson, Lisa M. Rimsza, Robin A. Roberts, Thomas M. Grogan, Thomas P. Miller, Larry W. Oberley, Margaret M. Briehl

Blood (2005) 106 (10): 3594–3601.

https://doi.org/10.1182/blood-2005-02-0487

Published: 2005

Journal Articles

Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.

Matthew W. Andres, DO, Robin A. Roberts, BS, Debbie J. Mustacich, PhD, Randy D. Gascoyne, MD, Deborah A. Fuchs, MD, Michael X. Wang, MD, Rita M. Braziel, MD, Wing C. Chan, MD, Thomas M. Grogan, MD, Lisa M. Rimsza, MD

Blood (2004) 104 (11): 4553.

https://doi.org/10.1182/blood.V104.11.4553.4553

Published: 2004

Journal Articles

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Lisa M. Rimsza, Robin A. Roberts, Thomas P. Miller, Joseph M. Unger, Michael LeBlanc, Rita M. Braziel, Dennis D. Weisenberger, Wing C. Chan, H. Konrad Muller-Hermelink, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Deborah A. Fuchs, Catherine M. Spier, Richard I. Fisher, Jan Delabie, Andreas Rosenwald, Louis M. Staudt, Thomas M. Grogan

Blood (2004) 103 (11): 4251–4258.

https://doi.org/10.1182/blood-2003-07-2365

Published: 2004

NARROW

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Loss of Major Histocompatibility Class II (MHCII) Gene Expression in Diffuse Large B Cell Lymphoma (DLBCL) Is Not Generally Due to Genetic Mutations in the Coding Regions of CIITA or RFX.

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only